Immunotherapy in Spain: Our Best Clinics and Costs 2024

Dr. Graupera is an awarded pediatric oncologist, one of the best bone and soft tissue sarcoma doctors. Heads the Hematology Oncology Department in Sant Joan De Déu — one of the best children’s hospitals in Europe. Researcher. Was trained in the USA. Specialty Provides treatments of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. Work experience Scientific Director of the Hematology Oncology Department in Sant Joan De Déu — Barcelona Children’s Hospital Director of the Developmental Tumors Laboratory in Sant Joan De Déu — Barcelona Children’s Hospital. Education 1990 — The Faculty of Medicine and Health Sciences at the University of Barcelona — Degree in general medicine and surgery 1995 — The Vall d'Hebron University Hospital — Specialty in pediatrics 1996-1999 — Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (USA) — Fellowship in pediatric hematology oncology 1999-2001 — Memorial Sloan Kettering Cancer Center (USA) — Fellowship in molecular pathology of pediatric cancer 2003 — The Autonomous University of Barcelona — PhD in Medicine. Awards 2000 — The Young Investigator Award by the American Society of Clinical Oncology 2001 — The Schweisguth Prize by the International Society of Pediatric Oncology for the best scientific article in pediatric oncology 2001 — The Career Development Award by the American Society of Clinical Oncology 2006 — The First Prize of the Spanish Association Against Cancer (AECC) award for the study of cancer in children 2011 — BBVA Foundation Award for the significant contributions in scientific research of pediatric cancer 2001 — The Schweisguth Prize by the International Society of Pediatric Oncology for the best scientific article in pediatric oncology. Scientific activity Dr. Jaume Mora Graupera has written over 70 papers on the malignant tumors treatment in children. Has developed a passive treatment for the spinal cord gliomas without radiation therapy. Membership in organizations The International Society of Pediatric Oncology (SIOP) The American Society of Clinical Oncology The American Association for Cancer Research The Spanish Society of Paediatric Hematology and Oncology The Catalan Society of Pediatrics The Histiocyte Society.

His main areas of interest lie in the breast cancer field, in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy that may occur both during adjuvant therapy and in metastatic disease. He has participated as a researcher in numerous phase 1, 2 and 3 studies, both in breast and melanoma, some of which have led to the approval of new drugs in new indications. He continues to work actively with other groups to drive the development of new drugs to help improve results in this patient group. In the field of melanoma, his main area of interest is centered on immunotherapy treatment. And along with all of the above there is patient care, always maintaining a holistic view of the patient, taking an interest in all the details that can happen in the evolution of their illness. Career Participant in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, as well as in developing trials for adjuvant disease. Participant in the studies that led to the approval of Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab, both of which revolutionized the treatment of this disease. Member of the Breast Cancer Unit and Melanoma Unit of the Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO).